Back to Results

Cardiol Therapeutics Inc Class A (CRDL)

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-fibrotic and anti-inflammatory therapies for heart diseases. Its lead candidate, CardiolRx, is being evaluated in a Phase III multinational, randomized, double-blind, placebo-controlled study for acute myocarditis and recurrent pericarditis. The company is also advancing CRD-38, a subcutaneous injection in preclinical development for heart failure. Cardiol Therapeutics holds a license agreement with Meros. Incorporated in 2017, the company is headquartered in Oakville, Canada, and its Class A common stock trades on the NASDAQ under the symbol CRDL.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CRDL
$1.61
-14.8% Downside
Fair
$8.40
344.2% Upside
Bargain
Fair
0.0%
November 12, 2026
12.8x
221.8 M
199.1 M
0.0%
78.7%
-20.4
70.7%
Valuation • Fair Value

Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) Fair Value by Valuation Model

Review the available estimates for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.61

Estimated downside of 14.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.26

Discounted cash flow valuation reference.

Comps Fair Value

$1.28

Comparable-company valuation reference.

Analyst Price Target

$8.40

Analysts imply upside of 344.2%.

How to read these valuation models

Use the 5 available valuation references for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-25.274 M

Current operating profitability reference.

EBITDA Forecast

-18.287 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

-20.4

Lower score that deserves closer risk review.

FCF / Net Income

70.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

51

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) Stock Forecast & Technical Outlook

Review Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) has a Strong Buy consensus, with 4 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 0
Sell 0
FAQ • Fast Investor Answers

Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) Stock FAQ

Data-supported answers about Cardiol Therapeutics Inc Class A (NASDAQ-CRDL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.61
Estimated downside 14.8%
Valuation Rating
Overvalued
Estimated downside of 14.8%
Analyst Target
$8.40
Implied upside 344.2%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is $1.61. This implies an estimated downside of 14.8% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 14.8% versus the current market price.

The available analyst price target for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is $8.40. The analyst target implies estimated upside of 344.2%.

The current financial health read for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is November 12, 2026.

The latest available data indicates no current dividend yield for Cardiol Therapeutics Inc Class A (NASDAQ-CRDL).

The current market capitalization listed for Cardiol Therapeutics Inc Class A is 221.8 M.

The current enterprise value listed for Cardiol Therapeutics Inc Class A is 199.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Cardiol Therapeutics Inc Class A is NASDAQ-CRDL, and the stock is listed on NASDAQ.

Cardiol Therapeutics Inc Class A (NASDAQ-CRDL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Cardiol Therapeutics Inc Class A is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Cardiol Therapeutics Inc Class A is 78.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B